PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022Hepatitis C is a liver infection caused b...
evaluating HCV regimens? Is pill burden a major unmet need in this indication? Which HCV regimen indevelopment are physici...
4.1.2pathophysiology244.1.3prognosis254.2symptoms255epidemiology275.1risk Factors And Comorbidities275.1.1the Risk Of Cont...
6.4france636.4.1diagnosis636.4.2clinical Practice646.5germany656.5.1diagnosis656.5.2clinical Practice656.6italy666.6.1diag...
8.2.3unmet Need: Disease Awareness988.2.4unmet Need: Treatment Cost998.2.5unmet Need: Shorter Treatment Duration1008.2.6un...
10.4.5idenix17010.4.6presidio17011market Outlook17211.1global Markets17211.1.1forecast17211.1.2drivers And Barriers &ndash...
11.10.3drivers And Barriers23512appendix23712.1bibliography23712.2abbreviations25512.3methodology25612.4forecasting Method...
Website: http://www.researchmoz.us/PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022
Upcoming SlideShare
Loading in...5
×

PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022

247

Published on

Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche’s Pegasys and Merck’s PegIntron) and ribavirin (e.g., Roche’s Copegus and Merck’s Rebetol) are used to treat HCV infection.

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
247
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022

  1. 1. PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronicpresentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchyskin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently,drug combinations containing pegylated interferon (e.g., Roche’s Pegasys and Merck’sPegIntron) and ribavirin (e.g., Roche’s Copegus and Merck’s Rebetol) are used to treat HCVinfection.Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy,such as Merck’s Victrelis (boceprevir) or Vertex’s Incivek (telaprevir). The entrance ofnext-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm.GlobalData expects a dramatic shift favoring the uptake of interferon-free regimens due to their more tolerableside-effect profiles and decreased duration of therapy compared with the current standard of care.ScopeOverview of hepatitis C virus, including epidemiology, etiology, general symptoms from infection, andnational vaccination recommendations and guidelines. Annualized hepatitis C therapeutics market revenue,annual cost of vaccination and treatment usage pattern data from 2012 and forecast for nine years to 2022. Keytopics covered include strategic competitor assessment, market characterization, unmet needs, clinical trialmapping and implications for the hepatitis C market. Pipeline analysis: comprehensive data split acrossdifferent phases, and emerging trends, specifically interferon-free therapies and fixed-dose combinations.Analysis of the current and future market competition in the global hepatitis C therapeutics market. Insightfulreview of the key industry and governmental drivers, restraints and challenges. Each trend is independentlyresearched to provide qualitative analysis of its implications.Market Model FeaturesAn interactive excel forecast model based on primary research interviews and surveys with KOLs andhigh-prescribing physicians is included in this report*. This patient based model provides diagnosis rates,patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, ourmodels support data presented in the reports and the complete methodology is outlined in the report and themodel.*Model only available with site and global license purchases.Key FindingsPatient awareness is anticipated to increase in response to government education and screening initiatives.Interferon use is predicted to decrease over the next 10 years. The launch of next-generation, direct-actingantivirals is expected to streamline the HCV treatment algorithm. The approval of more-tolerable HCVtherapies is likely to result in patients deciding to undergo treatment (i.e., decrease in the warehouse effect).Key Questions Answered in this ReportWhat is the fate of Vertex’s Incivek and Merck’s Victrelis after the launch of next-generationHCV therapies? What role, if any, will interferon have in the HCV treatment algorithm over the next decade?Is there demand from physicians for new interferon derivatives? What metrics do physicians use whenPharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022
  2. 2. evaluating HCV regimens? Is pill burden a major unmet need in this indication? Which HCV regimen indevelopment are physicians most excited about? As direct-acting antivirals (DAAs) overtake the HCVtreatment algorithm, is there any need for host-targeting therapies?Key BenefitsDevelop and design your in-licensing and out-licensing strategies through a review of pipeline products andtechnologies, and by identifying the companies with the most robust pipeline. Develop business strategies byunderstanding the trends shaping and driving the global hepatitis C therapeutics market. Drive revenues byunderstanding the key trends, innovative products and technologies, market segments, and companies likely toimpact the global hepatitis C market in future. Formulate effective sales and marketing strategies byunderstanding the competitive landscape and by analyzing the performance of various competitors. Identifyemerging players with potentially strong product portfolios and create effective counter-strategies to gain acompetitive advantage. Track drug sales in the global hepatitis C therapeutics market from 2012–2022.Organize your sales and marketing efforts by identifying the market categories and segments that presentmaximum opportunities for consolidations, investments and strategic partnerships.table Of Contents1table Of Contents21.1list Of Tables91.2list Of Figures122hcv: Executive Summary142.1hcv Market Is Expected To Grow During The Forecast Period142.2pharma Giants Battle As New Entrants Leverage Next-generation Hcv Regimens To Capture MarketShare162.3companies Prioritize Improving The Side Effect Profile And Duration Of Therapy Of Hcv Regimens172.4new Entrants Welcomed In The Market After The Launch Of Next-generation Hcv Regimens172.5launch Of Interferon-free Regimens Will Fundamentally Change The Hcv Treatment Algorithm In TheUs, Japan, And Many European Countries182.6what Do The Physicians Think?193introduction203.1catalyst203.2related Reports203.3upcoming Related Reports204disease Overview214.1etiology And Pathophysiology214.1.1etiology21PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022
  3. 3. 4.1.2pathophysiology244.1.3prognosis254.2symptoms255epidemiology275.1risk Factors And Comorbidities275.1.1the Risk Of Contracting Hcv Is Almost 50 Times Higher Among Injection Drug Users285.1.2there Is A 10.9-fold Increased Risk Of Developing Hcv Infection Through A Blood Transfusion285.1.3no Current Preventative Therapy To Reduce Perinatal Transmission295.1.4metabolic Syndrome Is A Common Comorbidity In Hcv-infected Individuals295.1.5chronic Alcoholism Greatly Magnifies The Risk Of Hcc305.1.6hepatitis B Virus And Hcv Share Similar Modes Of Transmission, Resulting In Co-infections305.1.7hcv/hiv Co-infection Complicates Treatment Options And Accelerates Liver Damage305.2global Trends315.2.1us315.2.25eu325.2.3japan345.2.4brazil355.2.5china355.3forecast Methodology365.3.1sources Used365.3.2forecast Assumptions And Methods395.3.3forecast Assumptions And Methods (hcv Genotypes)425.3.4sources Not Used455.4epidemiology Forecast (2012–2022)455.4.1total Prevalent Cases Of Hcv455.4.2age-specific Prevalent Cases Of Hcv475.4.3sex-specific Prevalent Cases Of Hcv505.4.4age-standardized Prevalence Of Hcv525.4.5hcv Genotype Class Distributions535.5discussion545.5.1conclusion On Epidemiology Trends545.5.2limitations Of The Analysis555.5.3strengths Of The Analysis556disease Management576.1diagnosis And Referral Overview576.2treatment Overview576.3us606.3.1diagnosis606.3.2clinical Practice61PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022
  4. 4. 6.4france636.4.1diagnosis636.4.2clinical Practice646.5germany656.5.1diagnosis656.5.2clinical Practice656.6italy666.6.1diagnosis666.6.2clinical Practice666.7spain676.7.1diagnosis676.7.2clinical Practice676.8uk676.8.1diagnosis676.8.2clinical Practice686.9japan696.9.1diagnosis696.9.2clinical Practice696.10brazil706.10.1diagnosis706.10.2clinical Practice706.11china706.11.1diagnosis706.11.2clinical Practice717competitive Assessment727.1overview727.2strategic Competitor Assessment727.3product Profiles – Major Brands737.3.1incivek (telaprevir)737.3.2victrelis (boceprevir)797.3.3pegasys (peginterferon Alfa-2a)837.3.4pegintron (peginterferon Alfa-2b)887.3.5copegus, Rebetol, And Generic Ribavirin927.3.6therapeutic Class: Interferon968opportunity And Unmet Need978.1overview978.2unmet Needs978.2.1unmet Need: Treatment Tolerability978.2.2unmet Need: Efficacy98PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022
  5. 5. 8.2.3unmet Need: Disease Awareness988.2.4unmet Need: Treatment Cost998.2.5unmet Need: Shorter Treatment Duration1008.2.6unmet Need: Simplified Treatment Regimens1008.3unmet Needs Gap Analysis1008.4opportunities1018.4.1opportunity: Pan-genotypic Hcv Regimen1018.4.2opportunity: Treatment Of Underrepresented Patient Populations1018.4.3opportunity: Involvement Of Immune System1029pipeline Assessment1039.1overview1039.2clinical Trial Mapping1039.2.1clinical Trials By Country1039.3clinical Trials By Phase And Trial Status1049.4promising Drugs In Clinical Development1059.4.1sofosbuvir And Sofosbuvir/ledipasvir1079.4.2simeprevir1169.4.3abt-450 Plus Abt-267 And Abt-3331239.4.4faldaprevir And Faldaprevir Plus Bi 2071271299.4.5daclatasvir And Daclatasvir Plus Asunaprevir1369.4.6vaniprevir1459.4.7other Drug Classes14910current And Future Players15310.1overview15310.2trends In Corporate Strategy15510.3company Profiles15510.3.1merck15510.3.2roche15710.3.3vertex15810.3.4janssen16010.3.5gilead16110.3.6abbvie16310.3.7bristol-myers Squibb16410.3.8boehringer Ingelheim16610.4additional Companies With Promising Drugs16710.4.1mitsubishi Tanabe16710.4.2glaxosmithkline16810.4.3achillion16910.4.4scynexis169PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022
  6. 6. 10.4.5idenix17010.4.6presidio17011market Outlook17211.1global Markets17211.1.1forecast17211.1.2drivers And Barriers – Global Issues17511.2us17911.2.1forecast17911.2.2key Events18411.2.3drivers And Barriers18511.3france18811.3.1forecast18811.3.2key Events19311.3.3drivers And Barriers19411.4germany19511.4.1forecast19511.4.2key Events20011.4.3drivers And Barriers20011.5italy20211.5.1forecast20211.5.2key Events20511.5.3drivers And Barriers20611.6spain20711.6.1forecast20711.6.2key Events21111.6.3drivers And Barriers21211.7uk21311.7.1forecast21311.7.2key Events21711.7.3drivers And Barriers21811.8japan22011.8.1forecast22011.8.2key Events22411.8.3drivers And Barriers22511.9brazil22611.9.1forecast22611.9.2key Events23011.9.3drivers And Barriers23011.10china23111.10.1forecast23111.10.2key Events234PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022
  7. 7. 11.10.3drivers And Barriers23512appendix23712.1bibliography23712.2abbreviations25512.3methodology25612.4forecasting Methodology25612.4.1percent Drug-treated Patients25712.4.2patient Warehousing25712.4.3drugs Included In Each Therapeutic Class25712.4.4launch And Patent Expiry Dates25712.4.5general Pricing Assumptions25812.4.6individual Drug Assumptions25912.4.7generic Erosion26112.4.8selection Of Pipeline Agents26112.4.9pricing Of Pipeline Agents26112.5physicians And Specialists Included In This Study26512.6survey Of Prescribing Physicians26712.7about The Authors26812.7.1author26812.7.2epidemiologist26812.7.3global Head Of Healthcare26812.8about Globaldata26912.9contact Us26912.10disclaimer269ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market researchreports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with ourhuge collection of market research reports. We provide our services to all sizes of organizations and across allindustry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well aspublishers and will assist you in making an informed decision by giving you unbiased and deep insights onwhich reports will satisfy your needs at the best price.Contact:M/s Sheela,90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usPharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022
  8. 8. Website: http://www.researchmoz.us/PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022

×